What is Onivyde?
Onivyde (nal-IRI) is an encapsulation of irinotecan, a topoisomerase I inhibitor, in a liposome. It is indicated for the treatment of adult patients with metastatic pancreatic adenocarcinoma who have progressed on or after gemcitabine-based chemotherapy [1].
How does Onivyde work?
Onivyde's liposomal formulation is designed to deliver irinotecan to the tumor site more effectively. In the body, the liposomes are thought to accumulate in tumor tissues. Once inside the tumor, the irinotecan is released and inhibits topoisomerase I, an enzyme crucial for DNA replication and cell division. This inhibition leads to DNA damage and ultimately cell death, particularly in rapidly dividing cancer cells [1].
When does the Onivyde patent expire?
Information on the specific patent expiry dates for Onivyde is publicly available through resources like DrugPatentWatch.com [2]. Patent landscapes for branded drugs can be complex, involving multiple patents covering composition of matter, manufacturing processes, and methods of use, each with its own expiration date.
What are the risks associated with Onivyde treatment?
The most common serious side effects of Onivyde include neutropenia (low white blood cell count), diarrhea, vomiting, and fatigue [1]. Patients may also experience nausea, stomatitis (mouth sores), decreased appetite, and fever. Because of these risks, regular monitoring of blood counts and prompt management of side effects are essential during treatment [1].
Are there alternative treatments for pancreatic cancer?
Treatment options for metastatic pancreatic cancer depend on various factors, including the patient's overall health, previous treatments, and the specific genetic makeup of the tumor. Beyond Onivyde, other chemotherapy regimens, targeted therapies, and immunotherapies are used, sometimes in combination [3]. Clinical trials also continue to explore novel agents and treatment strategies.
What is the outlook for generic Onivyde?
The availability of generic versions of Onivyde is contingent on patent expiry and potential legal challenges. Once patents expire, and if regulatory approval is obtained, generic manufacturers can produce and market lower-cost versions of the drug. This process can significantly impact treatment accessibility and costs for patients [2].
---
Sources:
[1] https://www.onivyde.com/
[2] https://drugpatentwatch.com/
[3] https://www.cancer.org/cancer/types/pancreatic-cancer/treatment.html